FAIR Health：2025年肥胖症与GLP-1药物：一项基于理赔数据的分析报告（英文版）

Obesity is a common and serious disease. In recent years, a new class of medications for obesity has become available: glucagon-like peptide-1 (GLP-1) receptor agonists. In this report, FAIR Health delves into its repository of over 51 billion commercial healthcare claim records, the nation’s largest such database, to examine trends in obesity and GLP-1 drug prescriptions among adult patients during the period 2019-2024. This study focuses on trends in diagnosis of overweight, obesity and